Clinical Trials Logo

Nasopharyngeal Neoplasms clinical trials

View clinical trials related to Nasopharyngeal Neoplasms.

Filter by:

NCT ID: NCT03806426 Active, not recruiting - Clinical trials for Familial Adenomatous Polyposis

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

Start date: December 5, 2018
Phase: Phase 3
Study type: Interventional

2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.

NCT ID: NCT03791944 Completed - Radiotherapy Clinical Trials

3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Verify that 3DV+TPS is non-inferior compared to existing imported TPS and superior to existing domestic TPS.

NCT ID: NCT03769467 Terminated - Clinical trials for Nasopharyngeal Carcinoma

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Start date: February 19, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC).

NCT ID: NCT03734809 Active, not recruiting - NPC Clinical Trials

NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer

Start date: May 3, 2019
Phase: Phase 2
Study type: Interventional

This is an open label, single arm, non-randomized, multi-site, phase 2 clinical trial of neoadjuvant pembrolizumab in combination with gemcitabine-cisplatin for 2 cycles,followed by concurrent pembrolizumab-cisplain-radiation, and then maintainence pembrolizumab monotherpy given every 3 weeks for a total treatment duration of 12 months, in previously untreated stage IVA ( UICC 8 th Edition ) nasopharyngeal cancer(NPC).

NCT ID: NCT03723343 Not yet recruiting - Clinical trials for Advanced Nasopharyngeal Carcinoma

GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma

Start date: October 18, 2018
Phase:
Study type: Observational [Patient Registry]

Mainly compared with GP induction chemotherapy combined with IMRT and TPF induction chemotherapy combined with IMRT in the treatment of nasopharyngeal carcinoma, the cure rate, remission rate, treatment of distant metastases and lymph node metastasis, quality of life improvement rate, etc.

NCT ID: NCT03701451 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma

Start date: February 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The study is to observe the efficacy and toxicity of demethylating drug decitabine and cisplatin induced chemotherapy for 3 cycles followed by concurrent chemoradiotherapy in the treatment of regionally advanced nasopharyngeal carcinoma,followed up for 2 years, observing the 2-year survival rate and variation of degrees of methylation before and after treatment,providing clinical basis for the clinical study of stage II-III.

NCT ID: NCT03700476 Active, not recruiting - Clinical trials for Nasopharyngeal Neoplasms

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

CONTINUUM
Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

The CONTINUUM trial plans to enroll patients with stage III-IVA (AJCC 8th, except T3N0-1 or T4N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC). Patients will be randomized in a 1:1 ratio to receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation or the same regimen plus Sintilimab. All patients will receive intensity-modulated radiotherapy (IMRT). Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 12 cycles.

NCT ID: NCT03688555 Completed - Clinical trials for Bilateral Nasal Polyposis

A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis

Start date: October 19, 2018
Phase: Phase 2
Study type: Interventional

The study will evaluate the effect of ACT-774312 on the nasal polyps and will assess the safety and tolerability of ACT-774312 in the patients with bilateral nasal polyposis

NCT ID: NCT03687515 Completed - Clinical trials for Chronic Rhinosinusitis With Polyposis

Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis.

Start date: January 1, 2015
Phase: Phase 3
Study type: Interventional

Topical and systemic steroids constitute the first choice in medical treatment for nasal polyps. This study aimed to evaluate the efficacy and safety of a short course of budesonide inhalation suspension via transnasal nebulization in the preoperative management of chronic rhinosinusitis with nasal polyposis. The second aim was to compare budesonide inhalation suspension with budesonide aqueous nasal spray and oral prednisone in nasal polyp treatment.

NCT ID: NCT03682055 Terminated - Clinical trials for Nasopharyngeal Carcinoma

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

Start date: April 4, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), as well as to evaluate the PK profile of VK-2019.